Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE: 688621)
Health Care · Life Sciences Tools & Services · CN
CN¥71.00
-2.41% today · +10.7% 1Y
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE: 688621) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $1.16B and employs 1,335 people.
Over the last twelve months the share price has gained 10.7%, trading between 46.68 and 80.70.
Tweenvest scores Beijing Sun-Novo Pharmaceutical Research Co., Ltd. across four factors: quality 71/100, value 38/100, growth 85/100, dividend 41/100. Its strongest factor is growth.
688621 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.16B
- Revenue (TTM)
- $155.77M
- P/E
- 157.42
- EPS
- 0.45
- Dividend yield
- 0.26%
- Beta (5Y)
- 0.10
- 52-week high
- CN¥80.70
- 52-week low
- CN¥46.68
- Avg volume (3M)
- —
- Shares outstanding
- 109.28M
- Employees
- 1,335
- Next earnings
- —
About Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. operates as a contract research organization (CRO) in China, primarily focused on the development of chemical and peptide-based pharmaceutical products. Its portfolio includes generic small-molecule chemical drugs and peptide therapies designed to treat a range of conditions such as impetigo, acne, renal anemia, hyperparathyroidism in chronic kidney disease patients on dialysis, and various pain-related ailments. Beyond drug development, the company offers a comprehensive array of research and evaluation services. These encompass testing for packaging material compatibility, detailed impurity profiling, extractables and leachables studies, and thorough safety assessments. Sun-Novo also provides support for consistency evaluations, facilitates clinical research, and delivers expert consulting and agency services for regulatory submissions. Furthermore, it conducts a full spectrum of GLP-compliant bioanalysis and pharmacokinetics-pharmacodynamics (PK/PD) studies, including pharmacokinetic, immunogenic, pharmacodynamic, and biomarker analyses. The company was founded in 2009 and is headquartered in Beijing, China.
- ISIN
- CNE100005139
- Founded
- 2009
- Listed since
- Jun 21, 2021
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Akums Drugs and Pharmaceuticals LimitedNSEI: AKUMS | $1.29B | Rs813.10 | -0.79% |
| Beijing Hotgen Biotech Co., Ltd.SHSE: 688068 | $1.24B | CN¥94.47 | +2.81% |
| Novogene Co., Ltd.SHSE: 688315 | $1.19B | CN¥19.77 | -3.09% |
| Maravai LifeSciences Holdings, Inc.NasdaqGS: MRVI | $1.18B | $7.07 | -10.51% |
| Gerresheimer AGXTRA: GXI | $1.12B | €28.56 | -1.52% |
| PharmaResources (Shanghai) Co., Ltd.SZSE: 301230 | $1.03B | CN¥38.48 | +0.79% |
| Anhui Wanbang Pharmaceutical Technology Co.,Ltd.SZSE: 301520 | $982.60M | CN¥71.05 | -4.23% |
| R&G PharmaStudies Co., Ltd.SZSE: 301333 | $952.14M | CN¥66.67 | +3.70% |
Figures last refreshed Oct 4, 2026.